UEG's content platform for gastroenterology education bringing recordings, courses, guidelines, and more together in one place.

Re-live UEG Week 2026 on Gutflix Gut Guide online What's new on Gutflix

Trending on Gutflix

Rate for better recommendations!

Your feedback helps us show you more of what you like and less of what you dislike!

More of this!

We will show you more similar content.

Not for me!

We won't suggest this again.

Bookmark!

Save this content for later!

New to myUEG? Create an account! Log In with myUEG account

UEG Poster

Standard Poster

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

GASTRIC MICROBIOTA GENDER DIFFERENCES IN HEALTHY STOMACH AND AUTOIMMUNE ATROPHIC GASTRITIS

Giulia Pivetta 1, Ludovica Dottori 1, Federico Fontana 2, Sophia Cingolani 1, Irene Ligato 1, Emanuele Dilaghi 3, Christian Milani 2, Marco Ventura 2, Marina Borro 4, Gianluca Esposito 5, Bruno Annibale 6, Edith Lahner 4

Affiliations

1 Sapienza University of Rome, Roma, Italy

2 University of Parma, Parma, Italy

3 Digestive and Liver Disease Unit of Sant'Andrea Hospital-Sapienza University of Rome, Rome, Italy

4 Sapienza University of Rome, Rome, Italy

5 Sant’Andrea Hospital, Sapienza University of Rome, Rome, Italy

6 University Hospital S. Andrea, Rome, Italy

Summary

AI Generated

A study of 52 subjects found that gender-specific differences in gastric microbiota composition observed in healthy individuals appear altered in autoimmune atrophic gastritis patients, potentially due to hypochlorhydria.

In healthy subjects, women had significantly higher bacterial abundance than men (704.65 vs 470.40, p=0.03) and lower biodiversity (Shannon index 3.2 vs 3.4, p=0.003), while in AAG patients these gender differences were reversed or absent.
AAG males showed significantly lower gastric microbiota biodiversity compared to healthy males (Shannon index 2.3 vs 3.4, p<0.001), whereas AAG females showed higher biodiversity than healthy females (3.5 vs 3.2, p=0.002).
At the genus level, Streptococcus was the most prevalent and was higher in healthy females versus males (11.26 vs 7.88, p=0.03) but similar in both genders in AAG (15.94 vs 15.49, p=0.77).
Several phylum-level differences were observed, including significantly higher Firmicutes in AAG males versus females (33.11 vs 27.46, p=0.0155) and higher Fusobacteria in healthy males versus females (1.31 vs 0.19, p=0.0124).
The authors conclude that the clinical impact of these gender-specific microbiota differences on the natural history of AAG remains to be determined.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Introduction

Gender differences are gaining increasing attention in autoimmune diseases, such as autoimmune atrophic gastritis (AAG). AAG is a chronic inflammatory pre-neoplastic condition that leads to atrophy of the oxyntic mucosa, resulting in hypochlorhydria and potentially leading to gastric neoplastic lesions. Recently, also the human microbiota has gained interest in the scientific community. Previous studies showed that AAG may be associated with modifications in the gastric microbiota composition likely due to hypochlorhydria, that makes plausible the overgrowth of intragastric bacteria. To our knowledge, data on gender differences in gastric microbiota are lacking.

Aims & Methods

In this study we aimed to investigate gender differences in the gastric microbiota composition in subjects with healthy stomachs and patients affected by AAG. This is a post-hoc analysis conducted on 52 adult subjects undergoing gastroscopy for dyspepsia: median age 61 years, range 18- 83, 32 females and 20 males; 30 (57.7%) with healthy stomach and 22 (42.3%) with AAG. Gastric biopsies were obtained for both histopathology and genomic DNA extraction. Gastric microbiota was assessed by sequencing hypervariable regions of the 16SrRNA gene. Bacterial profile at phylum and genus level was reported as relative abundance expressed as 16SrRNA OTUs (>0.5%) and biodiversity calculated as Shannon-diversity index-H. All data were stratified for female and male gender separately in healthy subjects and AAG patients.

Results

Healthy women had a significantly higher bacterial abundance compared to men; differently, in AAG patients, gastric bacterial abundance was similar in both genders (at 13333 reads, 704.65 in healthy women vs 470.40 in healthy males, p= 0.03; 467.2 in AAG females vs 433 in AAG males, p=0.32). In healthy subjects, the gastric microbiota showed a significantly lower biodiversity in females compared to males (3.2 vs 3.4, p=0.003). In contrast, in AAG patients, the gastric microbiota showed a significantly lower biodiversity in males than in females (Shannon index 2.3 vs 3.5, p<0.0001). Compared to healthy subjects, in AAG patients, the biodiversity of the gastric microbiota was significantly lower in males (2.3 vs 3.4, p<0.001), while it was higher in females (3.5 vs 3.2, p=0.002). Taxa frequency at phylum level in females and males is shown in the table. Concerning taxa frequency at genus level, Streptococcus was the most prevalent being higher in healthy females compared to males (11.26 vs 7.88, p=0.03), but similar in both genders in AAG (15.94 vs 15.49, p= 0.77).

Taxonomy phyla Healthy stomach	Females median	Males median	p - value	Taxonomy phyla AAG	Females median	Males median	p - value
Firmicutes	22.67	15.83	0.5677	Firmicutes	27.46	33.11	0.0155
Proteobacteria	18.70	26.41	0.8489	Proteobacteria	19.13	19.32	0.1425
Bacteroidetes	10.55	10.46	0.1824	Bacteroidetes	5.17	2.36	0.4042
Actinobacteria	2.97	1.75	0.6424	Actinobacteria	2.19	2.10	0.0042
Fusobacteria	0.19	1.31	0.0124	Fusobacteria	0.58	0.18	0.4634

Conclusion

Gastric microbiota gender differences in healthy subjects, seem to be reset in AAG, likely due to hypochlorhydria. Differences between genders on taxa frequency at phylum and genus level were observed in healthy subjects and AAG patients. The impact of these findings on the gender-specific natural history of AAG remains to be elucidated.

Conference

UEG Week Copenhagen 2023

Submission format

Abstract

Session

H. pylori at interfaces (Posters)

Citation

United European Gastroenterology Journal 2023; 11 (Supplement 8)

Published

2023

More Like This:

CLINICOPATHOLOGICAL CHARACTERISTICS AND LONG-TERM FOLLOW-UP PROGNOSIS OF PRIMARY ESD IN ECURA C-2 EARLY GASTRIC CANCER PATIENTS

Jing2 Zhang

DISTINCT ASSOCIATIONS OF GENERAL AND ESOPHAGEAL-SPECIFIC PSYCHOLOGICAL SYMPTOMS WITH POSTOPERATIVE PROGNOSIS AFTER ANTI-REFLUX SURGERY FOR REFRACTORY GERD

Zhongtao Zhang

DUPILUMAB FOR TREATMENT-REFRACTORY AND SEVERELY FIBROSTENOTIC PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: 1-YEAR OUTCOMES FROM THE “DESTRICT” PROSPECTIVE COHORT STUDY

Susan E. Moist

Introduction: Advanced chronic liver disease: When the liver gets stiff, the complications get going

Mattias Mandorfer

The role of behavioural treatments

Allison Malcolm

Q&A: Comparative discussion: Choosing the right tool for the right patient

UEG Presentation

New

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

CLINICOPATHOLOGICAL CHARACTERISTICS AND LONG-TERM FOLLOW-UP PROGNOSIS OF PRIMARY ESD IN ECURA C-2 EARLY GASTRIC CANCER PATIENTS

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

CLINICOPATHOLOGICAL CHARACTERISTICS AND LONG-TERM FOLLOW-UP PROGNOSIS OF PRIMARY ESD IN ECURA C-2 EARLY GASTRIC CANCER PATIENTS

Wei Wu 1, Jing2 Zhang 1

Affiliations

1 Peking University Third Hospital, Beijing, China

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Introduction

Early gastric cancer (EGC), defined as carcinoma confined to the mucosa or submucosa irrespective of lymph node metastasis, accounted for over 968,000 new cases and 660,000 deaths globally in 2022, ranking fifth in both incidence and mortality worldwide. Endoscopic submucosal dissection (ESD) has emerged as the standard minimally invasive treatment for EGC, demonstrating both safety and high curability. Patients meeting absolute or expanded indications for ESD achieve 5-year overall survival rates exceeding 90%. The 2021 JGCA guidelines (6th edition) introduced the endoscopic curability (eCura) categories to assess post-ESD curability, which guides subsequent management decisions.
For a part of eCura-C-2 patients, don not receive additional surgery may be acceptable. In this study, we aim to analysis the clinicopathological features and long-term prognosis of different lymph node metastasis risk categories.

Aims & Methods

Background and aims: Endoscopic submucosal dissection(ESD) is the standard treatment for early gastric cancer(EGC) meeting absolute indications, with post-ESD management guided by the eCura(endoscopic curability) categories. This study focused on eCura C-2 patients—those at high risk of lymph node metastasis(LNM)—and compared outcomes between surgical intervention and conservative management. We aimed to evaluate the clinical utility of the eCura scoring system in therapeutic decision-making for this population.
Method: This retrospective study included 103 eCura C-2 EGC patients treated with initial ESD at Peking University Third Hospital(2010–2023). Clinicopathological features were compared across LNM risk strata. Primary endpoints were overall survival(OS) and recurrence-free survival(RFS), assessed via Kaplan-Meier analysis with log-rank testing(statistical significance: p < 0.05).

Results

The LNM incidence demonstrated significant variation across risk groups: low-risk(1.9%), high-risk(12.5%), and intermediate-risk(0%). Survival analysis revealed no statistically significant difference in long-term OS between the surgical and non-surgical groups(5-year OS:100.0%vs91.2%,p=0.107). However, a significant disparity was observed in RFS, with the surgical group demonstrating superior outcomes compared to the non-surgical group(5-year RFS:100.0%vs.76.0%,p=0.009).Subgroup analysis revealed no significant difference in 5-year OS between surgical and non-surgical low-risk patients(100.0%vs88.9%,p=0.276), but RFS differed significantly(100.0%vs70.7%,p=0.046). Among intermediate/high risk patients, neither 5-year OS(100.0%vs96.0%,p=0.270) nor RFS(100.0% s93.8%, p=0.303) showed significant differences between groups.

Conclusion

The eCura scoring system effectively stratifies LNM risk in eCura C-2 patients, aiding treatment selection. While conservative strategy with close surveillance may be appropriate for elderly patients with severe comorbidities, surgical intervention improves long-term outcomes in operable candidates.

Event

UEG Week Barcelona 2026

Topics

Digestive Oncology Stomach & H. Pylori Mechanisms & Personalised Medicine Immunology Oesophagus

Submission format

Abstract

Session

Mapping molecular interactions in the upper gastrointestinal tract

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

CLINICOPATHOLOGICAL CHARACTERISTICS AND LONG-TERM FOLLOW-UP PROGNOSIS OF PRIMARY ESD IN ECURA C-2 EARLY GASTRIC CANCER PATIENTS

Jing2 Zhang

DISTINCT ASSOCIATIONS OF GENERAL AND ESOPHAGEAL-SPECIFIC PSYCHOLOGICAL SYMPTOMS WITH POSTOPERATIVE PROGNOSIS AFTER ANTI-REFLUX SURGERY FOR REFRACTORY GERD

Zhongtao Zhang

DUPILUMAB FOR TREATMENT-REFRACTORY AND SEVERELY FIBROSTENOTIC PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: 1-YEAR OUTCOMES FROM THE “DESTRICT” PROSPECTIVE COHORT STUDY

Susan E. Moist

Introduction: Advanced chronic liver disease: When the liver gets stiff, the complications get going

Mattias Mandorfer

The role of behavioural treatments

Allison Malcolm

Q&A: Comparative discussion: Choosing the right tool for the right patient

UEG Presentation

New

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

DISTINCT ASSOCIATIONS OF GENERAL AND ESOPHAGEAL-SPECIFIC PSYCHOLOGICAL SYMPTOMS WITH POSTOPERATIVE PROGNOSIS AFTER ANTI-REFLUX SURGERY FOR REFRACTORY GERD

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

DISTINCT ASSOCIATIONS OF GENERAL AND ESOPHAGEAL-SPECIFIC PSYCHOLOGICAL SYMPTOMS WITH POSTOPERATIVE PROGNOSIS AFTER ANTI-REFLUX SURGERY FOR REFRACTORY GERD

Zimeng Wang 1, Chenglin Xin 1, Zhi Zheng 1, Wei Wang 2, Xueqi Li 1, yixiao sun 1, Haiqiao Zhang 1, Qian Zhang 3, Xiaoye Liu 1, Wenyan Li 3, Fandong Meng 3, Yu Fu 4, Jie Yin 1, Jun Zhang 1, Yingchi Yang 1, Zhongtao Zhang 1

Affiliations

1 Beijing Friendship Hospital, Capital Medical University, Beijing, China

2 Beijing Anding Hospital, Capital Medical University, Beijing, China

3 State Key Lab of Digestive Health, Beijing, China

4 China General Microbiological Culture Collection Center, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Introduction

Anti-reflux surgery (ARS) is effective for refractory gastroesophageal reflux disease (rGERD) with abnormal acid exposure and positive symptom association. Although psychological processes may influence symptom perception, there is limited evidence on their prognostic role in rGERD after ARS. This study aims to evaluate their ability to predict postoperative health-related quality of life (HRQL) outcomes.

Aims & Methods

This retrospective cohort study enrolled rGERD patients with abnormal acid exposure and a positive symptom association who underwent laparoscopic Dor fundoplication between July 2021 and December 2024. Patient-reported outcomes, including HRQL, general anxiety and depressive symptoms, symptom-specific anxiety (ANX) and esophageal hypervigilance (HV), reflux and gastrointestinal symptoms, were assessed at baseline and 1-year postoperatively. The primary endpoint was a favorable prognosis, defined as >50% improvement in HRQL at 1-year postoperatively. Univariable and multivariable logistic regression models were used to identify baseline factors associated with unfavorable prognosis.

Results

	Univariate analysis		Adjusted analysis
Characteristics	Odds Ratio (95% CI)	P value	Odds Ratio (95% CI)	P value
Baseline- HADS
Neither Anxiety nor Depression	Reference		Reference
Anxiety only	5.33 (2.39–11.91)	<0.001	3.31 (1.61–6.79)	0.001
Depression only	4.00 (1.43–11.18)	0.008	6.81 (2.82–16.42)	<0.001
Comorbid Anxiety and Depression	3.05 (1.55 – 6.01)	0.001	5.89 (1.95–17.79)	0.002

Among 561 patients, 426 who achieved reflux normalization were stratified into favorable (n=362) and unfavorable (n=64) prognosis groups. In multivariable models, baseline depression and/or anxiety symptoms independently predicted an unfavorable prognosis, while comorbidity of ANX and HV at baseline was associated with a favorable prognosis. Physiological parameters showed no significant effect. The unfavorable-prognosis group had more severe depression, anxiety and postoperative flatulence, with flatulence correlating to baseline depression and anxiety symptoms. A subgroup exhibited persistent or worsening psychological symptoms despite objective reflux normalization.

Conclusion

In rGERD patients with objectively confirmed reflux undergoing ARS, baseline general anxiety and depressive symptoms were independently associated with unfavorable prognosis. This may be partly mediated by postoperative gastrointestinal symptoms, particularly flatulence.

References

1. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review
2. Systematic review: the burden of disruptive gastro-oesophageal reflux disease on health-related quality of life
3. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease
4. Majority of symptoms in esophageal reflux PPI non-responders are not related to reflux
5. Determinants of perception of heartburn and regurgitation
6. Determinants of gastro-oesophageal reflux perception in patients with persistent symptoms despite proton pump inhibitors
7. Characteristics of symptomatic reflux episodes on Acid suppressive therapy
8. Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburn
9. Finding relief for the self-conscious esophagus: laparoscopic anti-reflux surgery and the esophageal hypersensitivity and anxiety scale
10. Psychoemotional factors and their influence on the quality of life in patients with GERD
11. Esophageal Hypervigilance and Symptom-Specific Anxiety in Patients with Eosinophilic Esophagitis
12. Esophageal Hypervigilance and Anxiety Predict Post-Treatment Outcomes in Achalasia
13. Psychological Processes, Not Physiological Parameters, Are Most Important Contributors to Symptom Severity in Patients With Refractory Heartburn/Regurgitation Symptoms
14. Psychological symptoms do not discriminate between reflux phenotypes along the organic-functional refractory GERD spectrum
15. Association Between Psychosocial Disorders and Gastroesophageal Reflux Disease: A Systematic Review and Meta-analysis

Event

UEG Week Barcelona 2026

Topics

Stomach & H. Pylori Oesophagus

Submission format

Abstract

Session

Anti-secretory therapy: Evolving standards and future horizons

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

CLINICOPATHOLOGICAL CHARACTERISTICS AND LONG-TERM FOLLOW-UP PROGNOSIS OF PRIMARY ESD IN ECURA C-2 EARLY GASTRIC CANCER PATIENTS

Jing2 Zhang

DISTINCT ASSOCIATIONS OF GENERAL AND ESOPHAGEAL-SPECIFIC PSYCHOLOGICAL SYMPTOMS WITH POSTOPERATIVE PROGNOSIS AFTER ANTI-REFLUX SURGERY FOR REFRACTORY GERD

Zhongtao Zhang

DUPILUMAB FOR TREATMENT-REFRACTORY AND SEVERELY FIBROSTENOTIC PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: 1-YEAR OUTCOMES FROM THE “DESTRICT” PROSPECTIVE COHORT STUDY

Susan E. Moist

Introduction: Advanced chronic liver disease: When the liver gets stiff, the complications get going

Mattias Mandorfer

The role of behavioural treatments

Allison Malcolm

Q&A: Comparative discussion: Choosing the right tool for the right patient

UEG Presentation

New

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

DUPILUMAB FOR TREATMENT-REFRACTORY AND SEVERELY FIBROSTENOTIC PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: 1-YEAR OUTCOMES FROM THE “DESTRICT” PROSPECTIVE COHORT STUDY

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

DUPILUMAB FOR TREATMENT-REFRACTORY AND SEVERELY FIBROSTENOTIC PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: 1-YEAR OUTCOMES FROM THE “DESTRICT” PROSPECTIVE COHORT STUDY

Evan S. Dellon 1, Amy Brownlee 1, Lindsay M. Cortright 1, Kacie B. Walker 1, Grace Clark 1, Lilliana H. Soucaze 1, Julia R. Phillips 1, Ariel E. Sanderford 1, Craig C. Reed 1, Sherif Zaghloul 2, Cristina Almansa 3, Amr Radwan 4, Sabina deMarchi 4, Sheharyar Durrani 4, Susan E. Moist 1

Affiliations

1 University of North Carolina School of Medicine, Chapel Hill, NC, United States

2 Sanofi, Morristown, NJ, United States

3 Sanofi, Cambridge, MA, United States

4 Regeneron Pharmaceuticals Inc., Tarrytown, NY, United States

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Introduction

Dupilumab is approved for treatment of eosinophilic esophagitis (EoE), but its efficacy is unknown in patients with severe esophageal strictures or a need for frequent dilation, as they were excluded from the phase 3 LIBERTY EoE TREET trial.

Aims & Methods

We aimed to determine the proportion of treatment-refractory, severely fibrostenotic, dilation-dependent EoE patients who have histologic response and improvement in other EoE outcomes after dupilumab treatment. DESTRICT (NCT06352073) is a prospective, single-center, open-label cohort study of dupilumab 300 mg once weekly for up to 52 weeks. Patients aged ≥16 years, weighing ≥40 kg, and with histologically active EoE (peak eosinophil count [PEC] ≥15 eosinophils per high‑power field [eos/hpf]) were included if they had non-response or intolerance to proton‑pump inhibitors and topical corticosteroids (tCS) and a history of narrow-caliber EoE (stricture <10 mm or inability to pass an adult endoscope) or ≥4 prior esophageal dilations (≥2 of which were in the last year). Key exclusion criteria were systemic corticosteroids or tCS within 4 weeks prior to baseline endoscopy, use of biologics within 5 months, and non-EoE eosinophilic gastrointestinal diseases. Patients underwent endoscopy at baseline and 12, 24, and 52 weeks after starting dupilumab. The primary outcome was histologic response (defined as PEC <15 eos/hpf) at 24 weeks. Additional outcomes included minimum esophageal diameter, Endoscopic Reference Score (EREFS; range 0–9), EoE Histologic Scoring System (EoEHSS; range 0–1), Index of Severity for EoE (I-SEE; range 0–78), EoE Symptom Activity Index Patient-Reported Outcome (EEsAI PRO; range 0–100), and safety.

Results

Here, we report interim results for the first 10 patients completing 52 weeks of dupilumab treatment (median age 30 [26–40] years; 90% male; median 11 [8–14] years of EoE prior to study entry). At baseline, all patients had severe disease (median [interquartile range] I‑SEE: 25 [23−25]) and were histologically and endoscopically active (PEC: 143 [74−163] eos/hpf; EREFS: 7 [7−8] with 6 [4−15] prior dilations). At Week 24, 80% had histologic response, with associated decreases in eosinophil counts, EREFS, EoEHSS, and I-SEE. At Week 52, 70% had ongoing histologic response (the other three patients had 15, 18, and 26 eos/hpf), with eosinophil counts decreasing to 6 (2−15) eos/hpf compared with baseline (P = 0.005; 96% decrease). EREFS decreased to 2 (1−3) (P = 0.004; 71% decrease), with decreases in both inflammatory (4 [4−5] to 0 [0−1]; P = 0.004) and fibrostenotic (3 [3−4] to 2 [1−2]; P = 0.005) subscores. Decreases were also seen at Week 52 in EoEHSS grade and stage scores (0.60 to 0.16 and 0.62 to 0.14, respectively; P = 0.005 for both), I-SEE score (25 [23−25] to 3.5 [1−4; P = 0.005] with 10% inactive/80% mild), and EEsAI PRO (27 [27−34] to 0 [0−12]; P = 0.006). Minimum esophageal diameter increased from 12 (10−13) mm to 17 (16−18) mm (P = 0.005; 42% increase), and 40% did not require esophageal dilation at Week 52. These outcomes were maintained or improved from Week 24. Dupilumab was generally well tolerated, with no medication-related serious adverse events. The most common adverse events were injection‑site reactions.

Conclusion

After 52 weeks of treatment with dupilumab, this treatment-refractory and severely fibrostenotic EoE population had histologic responses and improvements in other outcomes comparable to or better than those seen in less severe EoE patients. The study is ongoing to assess outcomes for the planned full study cohort (n = 20).

Disclosure

Dellon ES: AbbVie, Adare/Ellodi, Alfasigma, ALK, Allakos, Amgen, AnaptysBio, Apogee, Apollo, Aqilion, Arena/Pfizer, AstraZeneca, Bethanamist, Biocryst, Bryn, Calypso, Celgene/Receptos/Bristol Myers Squibb, Celldex, Cyted, Domain, Dr. Falk Pharma, EsoCap, Eupraxia, Ferring, GI Reviewers, GSK, Holoclara, Invea, Knightpoint, LucidDx, Nexstone Immunology/Uniquity, Nutricia, Parexel/Calyx, Phathom, Regeneron Pharmaceuticals Inc., Revolo, Robarts/Alimentiv, Roivant, Sanofi, Shire/Takeda, Target RWE, Third Harmonic Bio, Upstream Bio – consulting fees; Adare/Ellodi, Allakos, Arena/Pfizer, AstraZeneca, Celldex, Celgene/Receptos/Bristol Myers Squibb, Dr. Falk Pharma, Eupraxia, Ferring, GSK, Meritage, Miraca, Nutricia, Phathom, Regeneron Pharmaceuticals Inc., Revolo, Sanofi, Shire/Takeda, Uniquity – research funding; Allakos, Aqilion, Holoclara, Invea – educational grants.
Brownlee A, Cortright LM, Walker KB, Clark G, Soucaze LH, Phillips JR, Sanderford AE: No conflicts of interest.
Reed CC: GI Reviewers, AstraZeneca – consulting fees.
Zaghloul S, Almansa C: Sanofi – employees, may hold stock and/or stock options in the company.
Radwan A, deMarchi S, Durrani S: Regeneron Pharmaceuticals Inc. – employees and shareholders.
Moist SE: Apogee Therapeutics – advisory board.

Event

UEG Week Barcelona 2026

Topics

Mechanisms & Personalised Medicine Oesophagus Immunology

Submission format

Abstract

Session

Fire in the oesophagus: Mastering eosinophilic oesophagitis

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

CLINICOPATHOLOGICAL CHARACTERISTICS AND LONG-TERM FOLLOW-UP PROGNOSIS OF PRIMARY ESD IN ECURA C-2 EARLY GASTRIC CANCER PATIENTS

Jing2 Zhang

DISTINCT ASSOCIATIONS OF GENERAL AND ESOPHAGEAL-SPECIFIC PSYCHOLOGICAL SYMPTOMS WITH POSTOPERATIVE PROGNOSIS AFTER ANTI-REFLUX SURGERY FOR REFRACTORY GERD

Zhongtao Zhang

DUPILUMAB FOR TREATMENT-REFRACTORY AND SEVERELY FIBROSTENOTIC PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: 1-YEAR OUTCOMES FROM THE “DESTRICT” PROSPECTIVE COHORT STUDY

Susan E. Moist

Introduction: Advanced chronic liver disease: When the liver gets stiff, the complications get going

Mattias Mandorfer

The role of behavioural treatments

Allison Malcolm

Q&A: Comparative discussion: Choosing the right tool for the right patient

UEG Presentation

New

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Introduction: Advanced chronic liver disease: When the liver gets stiff, the complications get going

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

Introduction: Advanced chronic liver disease: When the liver gets stiff, the complications get going

Mattias Mandorfer 1

Affiliations

1 Medical University of Vienna, Vienna, Austria

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Event

Postgraduate Teaching Programme Barcelona 2026

Topics

Digestive Oncology Radiology & Imaging Small Intestine & Nutrition Hepatobiliary

Session

Advanced chronic liver disease: When the liver gets stiff, the complications get going

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

CLINICOPATHOLOGICAL CHARACTERISTICS AND LONG-TERM FOLLOW-UP PROGNOSIS OF PRIMARY ESD IN ECURA C-2 EARLY GASTRIC CANCER PATIENTS

Jing2 Zhang

DISTINCT ASSOCIATIONS OF GENERAL AND ESOPHAGEAL-SPECIFIC PSYCHOLOGICAL SYMPTOMS WITH POSTOPERATIVE PROGNOSIS AFTER ANTI-REFLUX SURGERY FOR REFRACTORY GERD

Zhongtao Zhang

DUPILUMAB FOR TREATMENT-REFRACTORY AND SEVERELY FIBROSTENOTIC PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: 1-YEAR OUTCOMES FROM THE “DESTRICT” PROSPECTIVE COHORT STUDY

Susan E. Moist

Introduction: Advanced chronic liver disease: When the liver gets stiff, the complications get going

Mattias Mandorfer

The role of behavioural treatments

Allison Malcolm

Q&A: Comparative discussion: Choosing the right tool for the right patient

UEG Presentation

New

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

The role of behavioural treatments

Allison Malcolm 1

Affiliations

1 University Of Sydney, Sydney, Australia

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Event

Postgraduate Teaching Programme Barcelona 2026

Topics

Neurogastroenterology & Motility Surgery Primary Care Small Intestine & Nutrition

Session

Chronic constipation: How to diagnose and treat this frequent condition in clinical practice

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

CLINICOPATHOLOGICAL CHARACTERISTICS AND LONG-TERM FOLLOW-UP PROGNOSIS OF PRIMARY ESD IN ECURA C-2 EARLY GASTRIC CANCER PATIENTS

Jing2 Zhang

DISTINCT ASSOCIATIONS OF GENERAL AND ESOPHAGEAL-SPECIFIC PSYCHOLOGICAL SYMPTOMS WITH POSTOPERATIVE PROGNOSIS AFTER ANTI-REFLUX SURGERY FOR REFRACTORY GERD

Zhongtao Zhang

DUPILUMAB FOR TREATMENT-REFRACTORY AND SEVERELY FIBROSTENOTIC PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: 1-YEAR OUTCOMES FROM THE “DESTRICT” PROSPECTIVE COHORT STUDY

Susan E. Moist

Introduction: Advanced chronic liver disease: When the liver gets stiff, the complications get going

Mattias Mandorfer

The role of behavioural treatments

Allison Malcolm

Q&A: Comparative discussion: Choosing the right tool for the right patient

UEG Presentation

New

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Q&A: Comparative discussion: Choosing the right tool for the right patient

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

Q&A: Comparative discussion: Choosing the right tool for the right patient

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Event

Postgraduate Teaching Programme Barcelona 2026

Topics

IBD

Session

Monitoring of disease activity in IBD

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

CLINICOPATHOLOGICAL CHARACTERISTICS AND LONG-TERM FOLLOW-UP PROGNOSIS OF PRIMARY ESD IN ECURA C-2 EARLY GASTRIC CANCER PATIENTS

Jing2 Zhang

DISTINCT ASSOCIATIONS OF GENERAL AND ESOPHAGEAL-SPECIFIC PSYCHOLOGICAL SYMPTOMS WITH POSTOPERATIVE PROGNOSIS AFTER ANTI-REFLUX SURGERY FOR REFRACTORY GERD

Zhongtao Zhang

DUPILUMAB FOR TREATMENT-REFRACTORY AND SEVERELY FIBROSTENOTIC PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: 1-YEAR OUTCOMES FROM THE “DESTRICT” PROSPECTIVE COHORT STUDY

Susan E. Moist

Introduction: Advanced chronic liver disease: When the liver gets stiff, the complications get going

Mattias Mandorfer

The role of behavioural treatments

Allison Malcolm